The first and only Vinorelbine generic approved by the Drug Administration of Vietnam (DAV), Vinorelbine is a semi-synthetic Vinca alkaloid used in combination with cisplatin as a treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC).

Vinorelbine is a semi-synthetic vinca alkaloid that is used in combination with cisplatin as a first-line treatment for patients with advanced or metastatic non-small cell lung cancer (NSCLC).

Petar Vazharov, General Manager of Lotus Pharmaceuticals, said that Vinorelbine softgels have been launched in more than 20 countries in Asia and Europe, and are now being successfully launched in Vietnam. The launch of Vinorelbine in Vietnam will provide a positive impact to the overall cancer product portfolio and bring high quality products to patients in Vietnam on a sustainable basis.

According to IQVIA, global sales of Vinorelbine will be approximately US$180 million in 2021. Vietnam is the leading market with a 7.5% growth rate in the last 3 years.